Sort
21,281 grants matching “influenza”
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses
$708,799Norbert Pardi · University Of Pennsylvania · R01 · FY2023 · AI
Public Health Epidemiology of Influenza Virus Infection and Control in China
$708,667Hong Chen · Chinese Ctr-Disease Control/Prevention · U01 · FY2020 · IP
Negative regulation of innate immunity in influenza virus infection
$708,660Jian-Dong Li · Georgia State University · R01 · FY2024 · AI
IL-2 Family Cytokines and their Receptors--Biology of the IL-7/TSLP Systems
$708,555Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2025 · HL
Immunomodulation for Heart Allograft Tolerance
$708,494Richard N Pierson · University Of Maryland Baltimore · U01 · FY2009 · AI
Software for Analyzing Biosequence Data
$708,479Webb Colby Miller · Pennsylvania State University, The · R01 · FY2010 · HG
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses
$708,446Jim Boonyaratanakornkit · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Factors influencing TRM responses in upper airway tissue
$708,098Pandurangan Vijayanand · La Jolla Institute For Immunology · U19 · FY2025 · AI
RESPIRATORY PATHOGENS RESEARCH CENTERS (RPRC)
$707,670David Topham · University Of Rochester · N01 · FY2014 · AI
ZFAND6 regulation of mitophagy and inflammation
$707,534Edward W Harhaj · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2025 · AI
Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing Antibodies
$707,436Paul De Figueiredo · Texas A&M University · R01 · FY2021 · AI
RAPID VACCINATION OF HARD TO REACH POPULATI0NS
$707,046New York Academy Of Medicine · R01 · FY2004 · DA
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains
$706,927Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2018 · AI
US Hospital Vaccine Effectiveness (VE) Network - Supplement
$706,839Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2019 · IP
Evaluation of Protective Immunity After Mucosal Vaccination Against Ebola Virus
$706,731Maria A Croyle · University Of Texas At Austin · U01 · FY2011 · AI
Dynamics of Influenza Transmission in Nicaraguan Households
$706,596Aubree L Gordon · University Of Michigan At Ann Arbor · R01 · FY2017 · AI
New Paradigms in Gene Regulation During Influenza Virus Infections
$706,543Curt M Horvath · Northwestern University · U01 · FY2012 · AI
New Treatment for Inflammation in Middle Ear Infections
$706,451Sharon L McCoy · 13therapeutics, Inc. · R44 · FY2007 · DC
Natural Killer cells and the Immunogenetics of COVID-19
$706,411Paul John Norman · University Of Colorado Denver · R01 · FY2024 · AI
Human mobility models to forecast disease dynamics and the effectiveness of public health interventions
$706,315Amy Wesolowski · Johns Hopkins University · R01 · FY2021 · AI
Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance
$706,103Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · AR
Small molecule inhibitory leads against influenza RdRp
$705,833Thomas Roy Webb · Sri International · R01 · FY2015 · AI
Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches
$705,630Timothy W Bickmore · Northeastern University · R01 · FY2023 · MD
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung
$705,521Ya-Wen Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · HL
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung
$705,521Ya-Wen Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · HL